Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT02053285
Official study title

Pilot Study of a Novel Type of CT Scan to Assess Treatment Response During Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer

Study summary

Dual-energy CT (DECT) provides information on the blood volume in tumors and lymph nodes. As tumors respond to treatment, preliminary data suggests that the blood volumes changes as well. Investigators are therefore using DECT to test whether it can be used on radiation treatment to rapidly assess response to treatment.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedNot specified

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Locally advanced

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 23, 2022 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Rush University Medical Center

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Rush University Medical Center
Interventions being studied
Not specified
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Disease setting
Locally advanced→
Treatment approach
Radiation therapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Patients aged greater than 18 years with a diagnosis of stage III non-small cell lung cancer.
  • Planned treatment with either definitive chemoradiotherapy or preoperative chemoradiotherapy followed by surgical resection.
  • PET-CT study within 4 weeks of next available DECT study.
  • Patients must have measurable primary and nodal disease, defined by at least one lesion (primary and lymph node) greater than 1 cm.
  • Kidney function sufficient to tolerate iodine-based CT contrast.
  • No allergy to iodine-based contrast.
  • Ability to understand and the willingness to sign informed consent.
Reasons someone may not be able to joinExclusion criteria
  • Participants with a prior history of thoracic radiotherapy.
  • Participants may not be receiving any other study agents.
  • Inability to tolerate CT contrast
  • Pregnant women are excluded from this study because radiotherapy has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with radiotherapy, breastfeeding should be discontinued if the mother is treated with radiotherapy. These potential risks may also apply to other agents used in this study.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Rush University Medical CenterChicago, Illinois

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 23, 2022. Always confirm current availability with the study team.

View original record ↗